Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

Pharmacokinetic/Pharmacodynamic Adequacy of Novel β-Lactam/β-Lactamase Inhibitors against Gram-Negative Bacterial in Critically Ill Patients

The optimal regimens of novel β-lactam/β-lactamase inhibitors (BLBLIs), ceftazidime/avibactam, ceftolozane/tazobactam, and meropenem/vaborbactam, are not well defined in critically ill patients. This study was conducted to identify optimal regimens of BLBLIs in these patients. A Monte Carlo simulati...

Full description

Bibliographic Details
Main Authors:	Ruiying Han, Dan Sun, Sihan Li, Jiaojiao Chen, Mengmeng Teng, Bo Yang, Yalin Dong, Taotao Wang
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	Antibiotics
Subjects:	novel β-lactam/β-lactamase inhibitors Gram-negative bacteria infection critically ill patients pharmacokinetics/pharmacodynamics Monte Carlo simulations
Online Access:	https://www.mdpi.com/2079-6382/10/8/993

Similar Items

Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians
by: Luigi Principe, et al.
Published: (2022-04-01)

Effect of β-Lactamase inhibitors on in vitro activity of β-Lactam antibiotics against Burkholderia cepacia complex species
by: Annelien Everaert, et al.
Published: (2016-11-01)

β-Lactam/β-Lactamase Inhibitor Combination Antibiotics Under Development
by: Angeliki Katsarou, et al.
Published: (2025-02-01)

Evaluation of Metallo-β-Lactamase Susceptibility Testing in a Physiologic Medium
by: Tomefa E. Asempa, et al.
Published: (2021-12-01)

β-Lactam Antibiotics and β-Lactamase Enzymes Inhibitors, Part 2: Our Limited Resources
by: Silvana Alfei, et al.
Published: (2022-04-01)

In vitro activity of new combinations of β-lactam and β-lactamase inhibitors against the Mycobacterium tuberculosis complex
by: Elin Economou Lundeberg, et al.
Published: (2023-10-01)

Role of β-Lactamase Inhibitors as Potentiators in Antimicrobial Chemotherapy Targeting Gram-Negative Bacteria
by: Song Zhang, et al.
Published: (2024-03-01)

In vitro effects of the new oral β-lactamase inhibitor xeruborbactam in combination with oral β-lactams against clinical Mycobacterium abscessus isolates
by: Izumi Yamatani, et al.
Published: (2024-07-01)

Drug Discovery in the Field of β-Lactams: An Academic Perspective
by: Lian M. C. Jacobs, et al.
Published: (2024-01-01)

Clinically Isolated β-Lactam-Resistant Gram-Negative Bacilli in a Philippine Tertiary Care Hospital Harbor Multi-Class β-Lactamase Genes
by: Alecks Megxel S. Abordo, et al.
Published: (2023-08-01)

Best practices: Appropriate use of the new β-lactam/β-lactamase inhibitor combinations, ceftazidime-avibactam and ceftolozane-tazobactam in South Africa
by: Adrian J. Brink, et al.
Published: (2022-10-01)

In-Vitro Selection of Ceftazidime/Avibactam Resistance in OXA-48-Like-Expressing <i>Klebsiella pneumoniae</i>: In-Vitro and In-Vivo Fitness, Genetic Basis and Activities of β-Lactam Plus Novel β-Lactamase Inhibitor or β-Lactam Enhancer Combinations
by: Snehal Palwe, et al.
Published: (2021-10-01)

Contribution of efflux pump hyperactivity to the resistance to new β-lactam-β-lactamase inhibitor combinations including ceftazidime-avibactam, aztreonam-avibactam, and imipenem-relebactam
by: Sung Pin Tseng, et al.
Published: (2024-12-01)

Biochemical exploration of β-lactamase inhibitors
by: Varshaa Arer, et al.
Published: (2023-01-01)

Carbapenems versus β-lactam and β-lactamase inhibitors for treatment of nosocomial pneumonia: A systematic review and meta-analysis
by: Huai Qin Cang, et al.
Published: (2023-10-01)

Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities
by: Elizabeth Story-Roller, et al.
Published: (2018-09-01)

β-Lactam potentiators to re-sensitize resistant pathogens: Discovery, development, clinical use and the way forward
by: Lekshmi Narendrakumar, et al.
Published: (2023-03-01)

Retrospective Assessment of the Treatment Effectiveness of β-lactam/β-lactamase Inhibitor and Carbapenem Groups Antibiotics in Upper Urinary Tract Infections Caused by Extended Spectrum β-lactamase Producing Escherichia coli and Klebsiella Pneumoniae
by: Enes ARDIÇ, et al.
Published: (2025-03-01)

In Vitro Activity of New β-Lactam–β-Lactamase Inhibitor Combinations and Comparators against Clinical Isolates of Gram-Negative Bacilli: Results from the China Antimicrobial Surveillance Network (CHINET) in 2019
by: Yan Guo, et al.
Published: (2022-08-01)

Influence of β-lactam pharmacodynamics on the systems microbiology of gram-positive and gram-negative polymicrobial communities
by: Nicholas M. Smith, et al.
Published: (2024-06-01)

Penicillin-Binding Protein Occupancy Dataset for 18 β-Lactams and 4 β-Lactamase Inhibitors in Neisseria gonorrhoeae
by: Silvia López-Argüello, et al.
Published: (2023-06-01)

In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae
by: Yu-Shan Huang, et al.
Published: (2023-06-01)

Expanding the β‐Lactamase Family in the Human Microbiome
by: Baolei Jia, et al.
Published: (2024-12-01)

Novel approach to overcome the β-lactam resistant bacteria using an actinobacterial inhibitory protein
by: Nada A. M. Abdelbary, et al.
Published: (2023-10-01)

Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis
by: Sara Alosaimy, et al.
Published: (2020-04-01)

Broad-Spectrum Inhibitors against Class A, B, and C Type β-Lactamases to Block the Hydrolysis against Antibiotics: Kinetics and Structural Characterization
by: Nabeela Farhat, et al.
Published: (2022-10-01)

In vitro evaluation of using ceftazidime/avibactam against carbapenem-resistant Acinetobacter baumannii
by: Nazanin Pouya, et al.
Published: (2024-09-01)

The Importance of Extended-Spectrum β-lactamases in Gram-Negative Enteric Bacilli and the Phenotypic Methods of detection
by: Davood Kalantar-Neyestanaki, et al.
Published: (2016-07-01)

β-Lactam Dosing in Critical Patients: A Narrative Review of Optimal Efficacy and the Prevention of Resistance and Toxicity
by: João Gonçalves Pereira, et al.
Published: (2022-12-01)

Synthesis and enzyme-based evaluation of analogues L-tyrosine thiol carboxylic acid inhibitor of metallo-β-lactamase IMP-1
by: Omid Khalili Arjomandi, et al.
Published: (2019-01-01)

Recommendations to Synthetize Old and New β-Lactamases Inhibitors: A Review to Encourage Further Production
by: Silvana Alfei, et al.
Published: (2022-03-01)

Vegetables and Fruit as a Reservoir of β-Lactam and Colistin-Resistant Gram-Negative Bacteria: A Review
by: Widad Chelaghma, et al.
Published: (2021-12-01)

Structural Insights for Core Scaffold and Substrate Specificity of B1, B2, and B3 Metallo-β-Lactamases
by: Yeongjin Yun, et al.
Published: (2022-01-01)

Evaluation of the β-Lactamase Disk Test Method in the Detection of Extended-Spectrum-β- Lactamases in Clinical Isolates of Multidrug-Resistant Pseudomonas aeruginosa
by: Davood Kalantar-Neyestanaki, et al.
Published: (2015-12-01)

Evaluation of the β-Lactamase Disk Test Method in the Detection of Extended-Spectrum-β-Lactamases in Clinical Isolates of Multidrug-Resistant Pseudomonas aeruginosa
by: Davood Kalantar-Neyestanaki Kalantar-Neyestanaki, et al.
Published: (2016-01-01)

Artificial Intelligence to Close the Gap between Pharmacokinetic/Pharmacodynamic Targets and Clinical Outcomes in Critically Ill Patients: A Narrative Review on Beta Lactams
by: João Gonçalves Pereira, et al.
Published: (2024-09-01)

Insights into the Effects and Mechanism of Andrographolide-Mediated Recovery of Susceptibility of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics
by: Qiang Ma, et al.
Published: (2023-02-01)

Synthesis and evaluation of 1, 2, 3-triazole benzoate derivatives for inhibition of serine β-lactamases in extensively drug resistant pathogenic E. coli strains
by: Harshal S. Oman, et al.
Published: (2023-12-01)

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
by: Anna Duda-Madej, et al.
Published: (2023-11-01)

AmpC β-lactamases producing Gram-negative clinical isolates from a tertiary care hospital
by: Shubhdeep Kaur, et al.
Published: (2016-01-01)